Developing novel therapeutics for serious rare conditions
Therachon is a global biotechnology company committed to making a difference in the lives of patients living with serious rare conditions.
We are assembling a growing best-in-disease pipeline that shows great promise in both Achondroplasia and Short Bowel Syndrome.
We are headquartered in Basel, Switzerland, with research labs in Nice, France and business operations in the New York area.
Therachon is granted Orphan Drug Designation in the European Union for Apraglutide for the Treatment of Short Bowel Syndrome
BASEL, Switzerland, Nov. 29, 2018 /PRNewswire/ — Therachon AG (“Therachon”), a clinical-stage biotechnology company focused on treating the root causes of rare conditions, today announced that the European Commission has granted Orphan Drug Designation…
Therachon Expands Rare Disease Pipeline with Acquisition of GLyPharma Therapeutic Inc.
BASEL, Switzerland, Oct. 9, 2018 /PRNewswire/ — Therachon AG (“Therachon”), a clinical-stage biotechnology company focused on treating root causes of rare conditions, today announced the acquisition of GLyPharma Therapeutic Inc. (“GLyPharma”) for…
Therachon Raises $60 Million Mezzanine Financing to Advance Lead Program in Achondroplasia and to Expand Rare Disease Pipeline – Jørgen Søberg Petersen, M.D., Ph.D., DMSc, MBA and Timothy Anderson to Join Board of Directors –
BASEL, Switzerland, August 9, 2018 – Therachon AG, a clinical-stage biotechnology company focused on rare diseases, today announced it has completed a $60 million mezzanine financing led by Novo Holdings and…